Focusing on Solutions to the Opioid Crisis, Foundation for Opioid Response Efforts (FORE) Announces Family- and Community-Based Initiatives to Prevent Substance Use Disorder and Overdose
July 20, 2021 11:00 ET
|
Foundation for Opioid Response Efforts
New York, July 20, 2021 (GLOBE NEWSWIRE) -- It is estimated that one in eight (8.7 million) children ages 17 or younger in the United States live in a household where at least one parent has had a...
Opioid Use Disorder Market Size 2021 | Is Projected to grow USD 4.81 billion in 2028 at a CAGR of 8.7%
May 12, 2021 06:24 ET
|
Fortune Business Insights
Pune, India, May 12, 2021 (GLOBE NEWSWIRE) -- Opioid Use Disorder Market Size| 2021 Covid-19 Impact On Automotive Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players,...
NABP Urges Passage of the Mainstreaming Addiction Treatment Act by 117th Congress
February 25, 2021 13:00 ET
|
National Association of Boards of Pharmacy
MOUNT PROSPECT, IL, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The National Association of Boards of Pharmacy® (NABP®) continues its call for the passage of the Mainstreaming Addiction Treatment Act to...
Opioid Use Disorder Market to Soar at 10.8% CAGR and Hit USD 4.50 Billion by 2026; Increasing Research in Opioids by Pharmaceuticals to Aid Market Expansion: Fortune Business Insights™
November 23, 2020 07:07 ET
|
Fortune Business Insights
Pune, India, Nov. 23, 2020 (GLOBE NEWSWIRE) -- The global Opioid Use Disorder Market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period....
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
August 31, 2020 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and...
Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
September 27, 2019 06:35 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of...
OPIOIDS AND HOMELESSNESS: STUDY IDENTIFIES STRATEGIES FOR COMBATTING BOTH
July 24, 2019 10:26 ET
|
Abt Associates
Rockville, Md., July 24, 2019 (GLOBE NEWSWIRE) -- Housing is vital to well-being, which makes addressing the link between opioid use disorder (OUD) and homelessness all the more important. To...
N.M. Cannabis Patient Enrollment on Track to Exceed 80,000 by Year End
June 07, 2019 14:24 ET
|
Ultra Health
ALBUQUERQUE, N.M., June 07, 2019 (GLOBE NEWSWIRE) -- The New Mexico Department of Health (NMDOH) added six new qualifying conditions for medical cannabis on Thursday, effectively raising the total...
Sen-Jam Pharmaceutical Underscores the Urgent Need to Revolutionize Pain Management and End the Opioid Epidemic at the 2019 StartUp Health Festival
February 13, 2019 08:00 ET
|
Sen-Jam Pharmaceutical
HUNTINGTON, N.Y., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Sen-Jam Pharmaceutical, a therapeutic company focused on bringing relief to the opioid crisis, was delighted to present at the 2019 StartUp Health...
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
January 22, 2019 07:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...